EDN1 and Hypercholesterolemia: Along the general line of the involvement of NO-mitigation of the decreased flow due to ET-1, in volunteers with hypercholesterolemia and insulin resistance, ETA, but not ETA/B receptor antagonism, increased flow (Cardillo et al., 2000; Shemyakin et al., 2006).